SENTI-202, a Selective, Off-the-Shelf, Preclinical CAR-NK Cell Therapy with CD33 and/or FLT3 Activating CAR, Healthy Cell Protection from Endomucin (EMCN) Inhibitory CAR and Calibrated Release IL-15 for Hematologic Malignancies Including AML

Brian Garrison, Han Deng, Gozde Yucel, Nicholas Frankel, Russell Gordley, Michelle Hung, Derrick Lee, Marcus Gainer, Assen Roguev, Wesley Gorman, Nelia Leemans, Alice Lam, Yongshuai Li, Wilson Wong, Kanya Rajangam, Philip Lee, Timothy Lu

View PDF